Emergent Debt To Equity from 2010 to 2024
| EBS Stock | USD 6.67 1.11 19.96% |
Debt To Equity | First Reported 2010-12-31 | Previous Quarter 1.33020176 | Current Value 1.4 | Quarterly Volatility 0.58946678 |
Check Emergent Biosolutions financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Emergent Biosolutions' main balance sheet or income statement drivers, such as Depreciation And Amortization of 158.9 M, Interest Expense of 45 M or Total Revenue of 1.4 B, as well as many indicators such as Price To Sales Ratio of 0.11, Dividend Yield of 0.018 or PTB Ratio of 0.18. Emergent financial statements analysis is a perfect complement when working with Emergent Biosolutions Valuation or Volatility modules.
Emergent | Debt To Equity |
Latest Emergent Biosolutions' Debt To Equity Growth Pattern
Below is the plot of the Debt To Equity of Emergent Biosolutions over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Emergent Biosolutions' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Emergent Biosolutions' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.56 % | 10 Years Trend |
|
Debt To Equity |
| Timeline |
Emergent Debt To Equity Regression Statistics
| Arithmetic Mean | 0.49 | |
| Coefficient Of Variation | 121.00 | |
| Mean Deviation | 0.40 | |
| Median | 0.52 | |
| Standard Deviation | 0.59 | |
| Sample Variance | 0.35 | |
| Range | 2.4466 | |
| R-Value | 0.84 | |
| Mean Square Error | 0.11 | |
| R-Squared | 0.71 | |
| Significance | 0.000077 | |
| Slope | 0.11 | |
| Total Sum of Squares | 4.86 |
Emergent Debt To Equity History
About Emergent Biosolutions Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Emergent Biosolutions income statement, its balance sheet, and the statement of cash flows. Emergent Biosolutions investors use historical funamental indicators, such as Emergent Biosolutions's Debt To Equity, to determine how well the company is positioned to perform in the future. Although Emergent Biosolutions investors may use each financial statement separately, they are all related. The changes in Emergent Biosolutions's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Emergent Biosolutions's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Emergent Biosolutions Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Emergent Biosolutions. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 1.33 | 1.40 |
Pair Trading with Emergent Biosolutions
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Emergent Biosolutions position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will appreciate offsetting losses from the drop in the long position's value.Moving together with Emergent Stock
| 0.7 | LLY | Eli Lilly Sell-off Trend | PairCorr |
Moving against Emergent Stock
| 0.76 | IRWD | Ironwood Pharmaceuticals | PairCorr |
| 0.74 | CVS | CVS Health Corp Aggressive Push | PairCorr |
| 0.73 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.7 | COLL | Collegium Pharmaceutical | PairCorr |
| 0.67 | PBH | Prestige Brand Holdings | PairCorr |
The ability to find closely correlated positions to Emergent Biosolutions could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Emergent Biosolutions when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Emergent Biosolutions - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Emergent Biosolutions to buy it.
The correlation of Emergent Biosolutions is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Emergent Biosolutions moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Emergent Biosolutions moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Emergent Biosolutions can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.